Q-omics provides the consensus-scored NDRG2 profile across patient tissues and cancer cell-line models. NDRG2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NDRG2 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, NDRG2 protein abundance shows 28,966 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where NDRG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDRG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDRG2 survival associations across molecular data types. NDRG2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDRG2 RNA expression–survival associations across cancer types. High NDRG2 expression shows favorable associations in KIRP, KIRC, MESO, LGG, UCEC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NDRG2 RNA expression.
This table summarizes NDRG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDRG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDRG2 shows lower tumor expression in HNSC, KIRC, THCA, KIRP, COAD and STAD. The HNSC box plot shows higher NDRG2 RNA expression in normal versus tumor tissue (log2 FC = −2.746, t-test p < 0.001).
This table shows molecular features associated with NDRG2 in patient tissues and cancer cell lines. In patient samples, NDRG2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDRG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
